<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2404">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349228</url>
  </required_header>
  <id_info>
    <org_study_id>ECC2020-03</org_study_id>
    <nct_id>NCT04349228</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals</brief_title>
  <acronym>COVID_2Pro</acronym>
  <official_title>Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abderrahmane Mami Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eshmoun Clinical Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datametrix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abderrahmane Mami Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a
      Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care
      Units, in Tunisia. Multicentric, Randomized Comparative Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, Multicentric, Randomized Controlled Study in Two Parallel Groups of 530
      Healthcare Professionals working in the Intensive Care Unit Exposed to Risk of COVID19
      Infection Taking Hydroxychloroquine (HCQ) (200 mg/day) VS Placebo
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    - Interest in the use of HCQ is controversial.
  </why_stopped>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm1:Hydroxychloroquine (HCQ) (200 mg / day) for at least 2 months or until potential contamination**.
Arm2:Placebo (1 tablet/day) for at least 2 months or until potential contamination**.
** If the participant is contaminated (COVID19+), he or she will be followed up by telephone according to the study schedule.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>As the trial is open-label and to preserve the validity of the trial, the measurement of the endpoint must be blinded by a third party (i.e., an evaluator who is not aware of the arm to which the patient has been assigned or the treatment the patient is receiving) using the PROBE (&quot;Prospective Randomized Open Blinded Endpoint&quot;) method.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic COVID(+) infection rate</measure>
    <time_frame>60 days</time_frame>
    <description>Clinical Examination: Symptomatic COVID(+) infection rate (from randomization to the onset of signs suggestive of Covid19 infection or to the end of the study at 60 days) The rate of COVID19 infections is defined by the occurrence of the clinical signs below:
Cough
Dyspnea
Fever
Myalgia
Arthralgia
Rhinorrhea
Anosmia
Asthenia, fatigability Confirmation of the above symptoms and COVID(+) PCR infection during the 60days treatment period.
Biological Examination :
Measurement of viral load
Ion, liver, kidney, haematological assessment
Electrical Examination: ECG</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID19</condition>
  <condition>Sars-CoV2</condition>
  <condition>Hydroxychloroquine</condition>
  <condition>Prophylaxis</condition>
  <condition>Healthcare Worker</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine (HCQ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exposed health care professionals working in the intensive care unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Exposed health care professionals working in the intensive care unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine (HCQ)</intervention_name>
    <description>Hydroxychloroquine (HCQ) 200mg/day</description>
    <arm_group_label>Hydroxychloroquine (HCQ)</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo of Hydroxychloroquine (HCQ) without any active substance</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo of Plaquenil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COVID-19 (-)

          -  Works in a medical intensive care unit exposed to COVID-19 infection

          -  18 years old &lt; age &lt; 65 years old

          -  Having given written consent for their participation in the study.

        Exclusion Criteria:

          -  Diagnosis of COVID-19+

          -  Retinopathies,

          -  Hydroxychloroquine or other prophylactic treatments for VIDOC19 within one month prior
             to inclusion and throughout the study.

          -  Hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of
             the other components of this drug,

          -  Contraindication to prophylactic use of chloroquine, e.g. liver failure, known
             epilepsy, creatinine clearance &lt; 30 ml/min.

          -  Inability to be monitored during the trial period

          -  Pregnancy and breastfeeding

          -  Psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalila Ben Khelil, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Abderrahmane Mami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eshmoun Clinical Research Centre/ HÃ´pital Abderrahmane Mami-Ariana</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Abderrahmane Mami Hospital</investigator_affiliation>
    <investigator_full_name>Dr Jalila Ben Khelil</investigator_full_name>
    <investigator_title>Head of department</investigator_title>
  </responsible_party>
  <keyword>HCQ</keyword>
  <keyword>prophylaxie</keyword>
  <keyword>Healthcare Worker</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>COVID19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

